A Study Of Osteopontin Predicts The Prognosis Of Patients With Non-small Cell Lung Cancer

Objective:Osteopontin(OPN), an extracellular matrix-secreted phosphorylated glycoprotein, has been reported overexpressed in many solid tumor and is associated with the prognosis of patients. As an important part of lung cancer, the high recurrence of non-small cell lung cancer(NSCLC) also attracted great attention of scientists. In this study, we investigated the expression of OPN and the relationship with prognosis of NSCLC patients. Methods:We compared the expression of these 28 matched cDNA between tumor and peritumoral tissue by realtime quantitative polymerase chain reaction(PCR) at the molecular level, and measured OPN expression in protein level among 163 NSCLC samples by immunohistochemical method. The differences of expression of OPN and its relationship with the clinicopathological factors and the outcomes of patients were analyzed by chi-square test and Kaplan-Meier survival curve. Rusults:We demonstrated that the expression of OPN in tumor site was much higher than the tissue adjacent to carcinoma(P=0.0046) and the percentages of positive OPN expression is 66.8%. By further analysis, we found OPN expression was significantly correlated with poor prognosis of NSCLC. Moreover, for early stage patients, the OS and DFS of OPN negative group were significantly higher than OPN positive group(P = 0.012, χ2=6.282; P < 0.001, χ2=18.844). For advanced stage patients, OPN expression was only associated with OS(P=0.046,χ2=3.976). Conclusions:These results suggest that OPN is commonly expressed in NSCLC and may guide the evaluation of prognosis with NSCLC, especially for early stage patients.